Eli Lilly
pharma 🏭 Expanding Indianapolis, IN · LLY · Public
Eli Lilly is aggressively expanding US manufacturing capacity with $21B+ invested in Indiana since 2020, including a new dedicated genetic medicine facility in Lebanon. The company's blockbuster weight-loss drugs (Mounjaro, Zepbound) and tirzepatide pipeline are driving strong financial performance and bullish analyst sentiment.
📢 Announced additional $4.5B investment across Indiana manufacturing sites and opened first dedicated genetic medicine facility in Lebanon, IN.
Maker of Mounjaro, Zepbound, and insulin products. Rapidly expanding US manufacturing footprint with $23B in new plant investments.
Employees
45,000
Mfg Plants
11
All Facilities
21
Activity
9/10
Type
Public
Plant Locations (21 mapped)
Manufacturing Plants (11)
Lilly San Diego Manufacturing (Chorus/ImClone legacy)
San Diego, CA
Small-scale biologics and clinical-stage manufacturing; formerly associated with Lilly's San Diego biotech presence
400 employees
Lilly Augusta Manufacturing Site (LEAP Expansion)
Augusta, GA
New $1.6B LEAP manufacturing investment announced 2023–2024; injectable medicine and API production for GLP-1 and diabetes portfolio; under construction/early operations
500 employees
Lilly Parenteral Products – Clinton
Clinton, IN
Secondary packaging and parenteral product support manufacturing
300 employees
Lilly Technology Center – Indianapolis (McCarty Street)
Indianapolis, IN
Active pharmaceutical ingredient (API) and formulation manufacturing; legacy large-scale insulin and biologics production
2,000 employees
Lilly Manufacturing – Indianapolis South (Kentucky Avenue)
Indianapolis, IN
Parenteral drug manufacturing, injectable formulations including insulin products
1,500 employees
Lilly Fegert Road Manufacturing Facility
Indianapolis, IN
Device assembly and auto-injector pen manufacturing for insulin delivery systems
800 employees
Lilly Lebanon Manufacturing Site
Lebanon, IN
New $2.1B+ manufacturing expansion site; GLP-1 incretin medicines including tirzepatide (Mounjaro/Zepbound) fill-finish and API; part of LEAP initiative
1,200 employees
Lilly Concord Manufacturing Site (LEAP)
Concord, NC
New $1B+ advanced manufacturing facility for injectable medicines; part of Lilly's LEAP (Lilly's investment in new manufacturing) expansion; producing tirzepatide and other biologics
1,000 employees
Lilly Research Triangle Park (RTP) Manufacturing
Durham, NC
Parenteral manufacturing and sterile fill-finish; oncology injectables and biologics
700 employees
Lilly Branchburg Manufacturing Site
Branchburg, NJ
Biologics manufacturing; antibody-based therapies including donanemab and other large-molecule products
600 employees
Lilly Pleasant Prairie Manufacturing (Nexus facility – API)
Pleasant Prairie, WI
API synthesis and chemical manufacturing operations; legacy small-molecule production supporting Lilly's oral medicines portfolio
350 employees
Other Facilities
Lilly Indianapolis Distribution Center
Indianapolis, IN · distribution
Primary US pharmaceutical distribution center; cold-chain insulin and biologic product warehousing and logistics
Lilly Lebanon Logistics & Distribution Hub
Lebanon, IN · distribution
New distribution infrastructure supporting Lebanon manufacturing campus; cold-storage for GLP-1 injectables
Eli Lilly and Company Global Headquarters
Indianapolis, IN · hq
Global corporate headquarters, Lilly Corporate Center campus
Lilly Research Labs – San Diego (Torrey Pines)
San Diego, CA · r&d
Neurodegeneration, oncology, and pain biology research; site of Lilly San Diego biotech innovation hub
Lilly Research Labs – South San Francisco
South San Francisco, CA · r&d
Biotech hub collaborative research; genomics and precision medicine research satellite office
Lilly Greenfield Laboratories
Greenfield, IN · r&d
Primary US R&D campus; drug discovery, preclinical research, toxicology, and pilot-scale manufacturing; large animal facility
Lilly Corporate Center R&D (Indianapolis)
Indianapolis, IN · r&d
Clinical research, medical affairs, regulatory, computational biology, and drug development headquarters R&D functions
Lilly Boston Innovation Hub
Cambridge, MA · r&d
External biotech collaborations, academic partnerships with MIT/Harvard; Kendall Square biotech ecosystem presence
Lilly Research Triangle Park (RTP) R&D Campus
Durham, NC · r&d
Immunology, oncology, and diabetes R&D; process sciences and analytical development for North Carolina manufacturing cluster
Lilly New York City Innovation Hub
New York, NY · r&d
Digital health, data science, and external innovation partnerships; Lilly digital health and AI R&D hub
Recent News
Signal: Eli Lilly Stock Remains a "Buy" After Earnings
Schaeffers Research · 5/6/2026
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Zacks Investment Research · 5/6/2026
If You Want to Beat the Market, Start With These 3 Stocks
24/7 Wall Street · 5/6/2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites
Reuters · 5/6/2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
PRNewsWire · 5/6/2026
Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly.
Barrons · 5/6/2026
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show
24/7 Wall Street · 5/5/2026
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
PRNewsWire · 5/5/2026
Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months
24/7 Wall Street · 5/4/2026
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
Zacks Investment Research · 5/4/2026
Lilly declares second-quarter 2026 dividend
PRNewsWire · 5/4/2026
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research · 5/4/2026
FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
Barrons · 5/4/2026
This Pharma Stock Keeps Earning My Money, Here's Why
24/7 Wall Street · 5/4/2026
Why Eli Lilly Stock Jumped This Week
The Motley Fool · 5/3/2026